Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset

对康复者在症状出现后长达 8 个月的时间内针对 SARS-CoV-2 刺突蛋白的体液免疫进行纵向分析

阅读:3
作者:Sai Priya Anand ,Jérémie Prévost ,Manon Nayrac ,Guillaume Beaudoin-Bussières ,Mehdi Benlarbi ,Romain Gasser ,Nathalie Brassard ,Annemarie Laumaea ,Shang Yu Gong ,Catherine Bourassa ,Elsa Brunet-Ratnasingham ,Halima Medjahed ,Gabrielle Gendron-Lepage ,Guillaume Goyette ,Laurie Gokool ,Chantal Morrisseau ,Philippe Bégin ,Valérie Martel-Laferrière ,Cécile Tremblay ,Jonathan Richard ,Renée Bazin ,Ralf Duerr ,Daniel E Kaufmann ,Andrés Finzi

Abstract

With the recent approval of highly effective coronavirus disease 2019 (COVID-19) vaccines, functional and lasting immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently under investigation as antibody levels in plasma were shown to decline during convalescence. Since the absence of antibodies does not equate to absence of immune memory, we evaluate the presence of SARS-CoV-2-specific memory B cells in convalescent individuals. Here, we report a longitudinal assessment of humoral immune responses on 32 donors up to 8 months post-symptom onset. Our observations indicate that anti-Spike and anti-receptor binding domain (RBD) immunoglobulin M (IgM) in plasma decay rapidly, whereas the reduction of IgG is less prominent. Neutralizing activity also declines rapidly when compared to Fc-effector functions. Concomitantly, the frequencies of RBD-specific IgM+ B cells wane significantly when compared to RBD-specific IgG+ B cells, which remain stable. Our results add to the current understanding of immune memory following SARS-CoV-2 infection, which is critical for secondary infection prevention and vaccine efficacy.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。